Novel Therapeutic Approaches in the Treatment of Multiple Myeloma

Last Modified: April 6, 2005

Share article

Conference Dates: May 19-20, 2005
Conference Location: Best Western Boston, The Inn at Longwood Medical, 342 Longwood Avenue, Boston, MA

Sponsoring Group: Dana-Farber/Partners CancerCare, Harvard Medical School, Multiple Myeloma Research Foundation

Conference Web Page URL:

Conference Objectives:

  1. Indentify the prognostic indicators and diagnostic approaches to multiple myeloma.
  2. Discuss the latest advances in stem cell transplantation, treatments for bone disease, and supportive care management.
  3. Describe the role and appropriate use of novel treatments for multiple myeloma throughout the disease progression.

Who Should Attend: Patients (May 19); Hematologists, Medical Oncologists, Oncology Nurses, Internists with Newly Diagnosed Patients

Registration Information: Patient Program, May 19: Contact the MMRF at 203-972-1250 or visit Professional Program, May 20:

Conference Fees: Free Patient Program, $25 Professional Registration

Continuing Education: Yes. 4 category 1 credits available for physicians.

ASH: Novel Drug Beneficial in Multiple Myeloma

May 24, 2015 - In patients with relapsed or resistant multiple myeloma who have received up to three prior therapies excluding the first-generation proteasome inhibitor bortezomib, treatment with the second-generation proteasome inhibitor carfilzomib is associated a hig

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More